Sign in
Taking peoplePhase 1/2

Nerve cell transplant from stem cells for recent spinal cord injury

Tests stem cell-derived nerve cells in recent spinal cord injury.

Key facts

Who runs it
S.Biomedics Co., Ltd.
Where
South Korea2 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC in AIS-A Level of Sub-acute SCI
Status
Recruiting
Phase
Phase 1/2
People taking part
5 people, planned
Started
23 Sept 2021
Expected to end
Sept 2030
Type of study
Interventional
Treatments tested
  • Neural precursor cells derived from human embryonic stem cell line
Record updated
18 May 2025

Who can take part

The trial is looking for adults with a recent, complete spinal cord injury in the neck (C4 to C7). They would receive nerve precursor cells made from a human embryonic stem cell line.

Age
18 to 65 years
Sex
All sexes
Disease stage
Sub-acute spinal cord injury: the cells must be given on Day 7 to 60 after the injury. The injury must be complete (AIS-A) at spinal level C4-C7.
Earlier treatment
People who have had cell treatments before cannot join. Blood transfusions are allowed.
Main reasons for not taking part
  • Injury caused by a penetrating wound, such as a gunshot or stab wound, or a spinal cord that is fully cut through
  • Several injured areas, or an injury longer than 2 cm (0.8 in) on MRI
  • History of cancer, weak immune system, active infection, hepatitis B or C, or HIV
  • Known allergy to basiliximab, tacrolimus, mycophenolate mofetil, methylprednisolone or prednisone
  • Cannot have general anesthesia or physical therapy
Show the full registry criteria (17)Hide the full registry criteria

Who can take part

  • Upon written consent of the patient or the legally acceptable representative of the patient
  • Male and female patients 18 to 65 years of age
  • Female patients who showed negative results on the pregnancy test, use an acceptable contraceptive or have no possibility of pregnancy (at least 2 years have elapsed after menopause or have undergone hysterectomy, ovariectomy, or sterilization operation), or male patients who have received vasectomy or are willing to use contraceptives for up to 90 days after administration of the investigational product using a dual contraceptive method*; *Dual contraceptive method: Method of using multiple contraceptives, such as using a cervical cap or contraceptive diaphragm in addition to a condom for males
  • Patients who are capable of being administered with the investigational product on Day 7 to 60 after spinal cord injury
  • Patients who have been confirmed to have spinal cord injury classified as AIS-A on ISNCSCI, SCIM and/or MRI by the investigator, physiatrist, or other spinal cord injury specialist
  • Patients whose ASIA Impairment Scale (AIS) satisfies AIS-A criteria (spinal segment within C4-C7, complete injury)

Who cannot take part

  • Patients incapable of receiving physical therapy or combination therapy
  • Patients with other complications, including neurological defects related to peripheral nerve injury (neuromuscular injury or central spinal cord syndrome), or etiological causes of paraplegia or sensorimotor defects related to an additional underlying condition
  • Patients with known hypersensitivity to basiliximab, tacrolimus, mycophenolate mofetil, methylprednisolone, or prednisone
  • Patients with the following intercurrent diseases or conditions:; Coagulopathy with INR> 1.4 at the time of administration of the investigational product (Day 0); Active infection; Active hypotension requiring vasoconstrictor treatment (less than 60 mmHg of diastolic blood pressure); Rupture of the skin on the area of surgery; Medical history of malignant tumor; Primary or secondary immunodeficiency; Clinically significant abnormal values discovered as a result of laboratory tests; Creatinine > 1.5 mg/dL; When the level found in the liver-function examination is more than twice the upper limit of the normal level; Hematocrit/hemoglobin <30%/10 g/dL; Total WBC < 1000/μL; Uncontrolled hypertension (systole> 180 mmHg or diastole> 100 mmHg); Uncontrolled diabetes (HbA1c> 8%); Evidence of GI bleeding on the stool guaiac test; Positive on tuberculosis test (However, a chest X-ray may be performed if found positive on the TB test, and the patient may be enrolled upon no findings that suggest active tuberculosis on the chest X-ray.); Hepatitis B or C; Human Immunodeficiency Virus (HIV); Substance abuse or alcoholism; Unstable or untreated psychiatric disorder
  • Patients with spinal cord injury caused by penetrating trauma such as gunshot or stab wounds
  • Patients with complete transection on the spinal cord
  • Patients with spinal cord injury that require more than the mono-segment treatment
  • Patients with multiple lesions or lesions longer than 2 cm in length found on MRI examination
  • Patients administered with cells excluding blood transfusion before participating in the clinical study
  • Patients incapable of going under general anesthesia due to other reasons
  • Patients judged unsuitable for participation in this clinical study by the investigator

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Spinal cord injury

This trial is currently available in South Korea.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study intends to evaluate the safety and exploratory efficacy of transplantation therapy using neural precursor cells (PSA-NCAM(+) NPC) derived from the human embryonic stem cell line for the treatment of paralysis and other related symptoms from sub-acute spinal cord injury.

The group in the trial

  • PSA-NCAM(+) NPCTreatment being tested

    Cells are administered through intrathecal injection. Injection is administered to a total of five areas.

    Treatment: Neural precursor cells derived from human embryonic stem cell line

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Single Center, Open Label, Single Group, Phase 1/2a Clinical Study to Evaluate the Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC Derived From hESC Line in AIS-A Level of Sub-acute SCI(From 7 to 60 Days)
Plain-language title
Nerve cell transplant from stem cells for recent spinal cord injuryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT04812431, who can take part
Record updated
18 May 2025